Buchanan, a WPP-owned financial communications advisory, and The Conscious Fund, the most active early-stage investor in the psychedelic medicine sector, are pleased to announce a partnership to support the burgeoning psychedelic medicine sector.
The partnership will be of benefit to the psychedelic medicine sector as it brings together Buchanan’s understanding of the media’s impact on global private and public capital markets and The Conscious Fund’s track record of investing in and nurturing quality psychedelic medicine companies. At the core of the partnership is an understanding that the psychedelic medicine sector requires widespread investment and education if it is to grow from a niche and become mainstream.
Henry Harrison-Topham, Partner and Head of Cannabis & Wellness at Buchanan, commented: “We very much look forward to working alongside The Conscious Fund, which has an exceptional track record in the space, and being of service to a select group of its portfolio companies. We believe we are the ideal communications partner for this fledgling industry due to our ability to convey a company’s investment proposition to the public and private capital markets through creative and impactful strategic communications.”
Richard Skaife, Partner at The Conscious Fund, added: “Since its inception, The Conscious Fund’s goal has been to grow companies within the psychedelic sector. The fund and the industry overall have been very successful to date but if psychedelic medicine is to achieve its potential in serving humanity, we must reach a larger and more generalist audience. This is why we are pleased to be working with Buchanan, which is part of WPP, the world’s largest communications group.”
Buchanan is a financial and corporate communications agency that is part of WPP plc, the world’s largest creative transformation company. Located in London and with an international reach via the WPP network of 3,000 offices across 111 countries, Buchanan accesses the global capital markets on behalf of its clients to achieve their corporate objectives.
Ariadna D. Peretz
Tel: +44 (0)20 7466 5000
About The Conscious Fund
The Conscious Fund is the most active early stage venture fund in the psychedelic medicine space. It invests into drug discovery, clinics, addiction programs, retreats, AI, telemedicine, media and training. Its global, platform-based approach helps to transform outcomes for patients with mental health, addiction and chronic pain issues.
The US$60 million fund has backed 14 of the leading companies in the sector, spanning drug discovery, clinics, addiction, AI, and media, and has incubated 13 projects, including The Psychedelic Medicine Association, the first psychedelic medicine SPAC, and Microdose, a profitable media company.
For further information, please visit www.theconscious.fund.
The Conscious Fund